Evidence map›Paper›PMID 38014258›Full record

ArticlebioRxiv : the preprint server for biology2023

High throughput screening of mesenchymal stromal cell morphological response to inflammatory signals for bioreactor-based manufacturing of extracellular vesicles that modulate microglia.

Andrew M Larey, Thomas M Spoerer, Kanupriya R Daga, Maria G Morfin, Hannah M Hynds, Jana Carpenter, Kelly M Hines, Ross A Marklein

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Andrew M LareySchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA, USA.
Thomas M SpoererSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA, USA.
Kanupriya R DagaSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA, USA.
Maria G MorfinRegenerative Bioscience Center, University of Georgia, Athens, GA, USA.
Hannah M HyndsDepartment of Chemistry, University of Georgia, Athens, GA, USA.
Jana CarpenterDepartment of Chemistry, University of Georgia, Athens, GA, USA.
Kelly M HinesDepartment of Chemistry, University of Georgia, Athens, GA, USA.
Ross A MarkleinSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA, USA.
University of Georgia · US

Funding

T32 Predoctoral training grant in GlycosciencesT32GM145467 · NIGMS · UNIVERSITY OF GEORGIA · PI I JONATHAN AMSTER, Robert S. Haltiwanger · 2022 to 2026
$1.2M
NIGMS NIH HHS T32 GM145467
6 · The paper itself

Abstract

Due to their immunomodulatory function, mesenchymal stromal cells (MSCs) are a promising therapeutic with the potential to treat neuroinflammation associated with neurodegenerative diseases. This function can be mediated by secreted extracellular vesicles (MSC-EVs). Despite established safety, MSC clinical translation has been unsuccessful due to inconsistent clinical outcomes resulting from functional heterogeneity. Current approaches to mitigate functional heterogeneity include 'priming' MSCs with inflammatory signals to enhance function. However, comprehensive evaluation of priming and its effects on MSC-EV function has not been performed. Clinical translation of MSC-EV therapies requires significant manufacturing scale-up, yet few studies have investigated the effects of priming in bioreactors. As MSC morphology has been shown to predict their immunomodulatory function, we screened MSC morphological response to an array of priming signals and evaluated MSC-EV identity and potency in response to priming in flasks and bioreactors. We identified unique priming conditions corresponding to distinct morphologies. These conditions demonstrated a range of MSC-EV preparation quality and lipidome, allowing us to discover a novel MSC-EV manufacturing condition, as well as gain insight into potential mechanisms of MSC-EV microglia modulation. Our novel screening approach and application of priming to MSC-EV bioreactor manufacturing informs refinement of larger-scale manufacturing and enhancement of MSC-EV function.

Indexed as

bioreactorextracellular vesiclehigh throughput screeninglipidomicsMesenchymal stromal cellmicroglia

Identifiers

PMID38014258
PMCPMC10680807
OpenAlexW4388814009

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.